{"name":"Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva","slug":"gruppo-italiano-per-la-valutazione-degli-interventi-in-terapia-intensiva","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Piperacillin-tazobactam combination product","genericName":"Piperacillin-tazobactam combination product","slug":"piperacillin-tazobactam-combination-product","indication":"Bacterial infections including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and respiratory tract infections","status":"marketed"}]}],"pipeline":[{"name":"Piperacillin-tazobactam combination product","genericName":"Piperacillin-tazobactam combination product","slug":"piperacillin-tazobactam-combination-product","phase":"marketed","mechanism":"Piperacillin-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.","indications":["Bacterial infections including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and respiratory tract infections","Nosocomial pneumonia","Febrile neutropenia in immunocompromised patients"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}